Company Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:29 06/02/2026 GMT			5-day change	1st Jan Change
356.40 ^CHF	-0.64%		+1.63%	+8.59%

08:41pm	Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial	RE
02-06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE

Business description: Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Number of employees: 103,249

Sales by Activity: Roche Holding AG

Fiscal Period: December	2021 (CHF)	2022 (CHF)	2023 (CHF)	2024 (CHF)	2025 (CHF)
Pharmaceuticals - Roche Pharmaceuticals	45.71B	46.35B	44.43B	46.34B	48.07B
Pharmaceuticals - Chugai	8.36B	9.27B	7.2B	6.88B	7.02B
Diagnostics	17.86B	17.82B	14.16B	14.46B	13.96B
Elimination	-6.08B	-7.02B	-5.35B	-5.29B	-5.7B

See all business segments

Geographical breakdown of sales: Roche Holding AG

Fiscal Period: December	2021 (CHF)	2022 (CHF)	2023 (CHF)	2024 (CHF)	2025 (CHF)
United States	28.06B	29.31B	28.35B	30.17B	30.72B
Rest of Europe	11.38B	10.33B	9.7B	10.29B	10.86B
China	-	-	-	-	4.82B
Rest of Asia	9.76B	9.85B	8.89B	9.08B	3.78B
Latin America	2.75B	2.87B	2.97B	3.25B	3.24B
Germany	4.32B	3.32B	2.89B	2.94B	3.12B
Japan	5.07B	6.45B	4.46B	3.29B	3.12B
Africa, Australia and Oceania	1.48B	1.52B	1.21B	1.25B	1.36B
Switzerland	2.12B	1.67B	1.12B	1.23B	1.34B
Rest of North America	916M	1.1B	838M	889M	982M

See all geographic segments

Executive Committee: Roche Holding AG

Manager	Title	Age	Since
Thomas Schinecker CEO	Chief Executive Officer	51	14/03/2023
Alan Hippe DFI	Director of Finance/CFO	59	05/06/2011
Wafaa Mamilli CTO	Chief Tech/Sci/R&D Officer	59	09/02/2025
Levi Garraway CTO	Chief Tech/Sci/R&D Officer	58	31/12/2022
Pascale Schmidt CMP	Compliance Officer	53	31/12/2019

See ROCHE HOLDING AG governance

Composition of the Board of Directors: Roche Holding AG

Director	Title	Age	Since
André Hoffmann BRD	Director/Board Member	67	31/12/1995
Severin Schwan CHM	Chairman	59	14/03/2023
Richard P. Lifton BRD	Director/Board Member	73	02/03/2015
Claudia Dyckerhoff BRD	Director/Board Member	59	29/02/2016
Anita Hauser BRD	Director/Board Member	57	13/03/2017
Joerg Duschmale BRD	Director/Board Member	42	16/03/2020
Patrick Frost BRD	Director/Board Member	58	16/03/2020
Jemilah Mahmood BRD	Director/Board Member	67	28/02/2022
Akiko Iwasaki BRD	Director/Board Member	56	28/02/2023
Ulf Mark Schneider BRD	Director/Board Member	61	28/02/2023

Composition of the Board of Directors

Shareholders: Roche Holding AG

Name	Equities	%	Valuation
State Street Global Advisors Ltd. 0.152 %	1,068,211	0.152 %	443 M CHF
Sjunde AP-fonden 0.1471 %	1,033,467	0.1471 %	429 M CHF
DWS CH AG 0.1119 %	786,201	0.1119 %	326 M CHF
Baloise Asset Management AG 0.1043 %	732,464	0.1043 %	304 M CHF
Eurizon Capital SGR SpA 0.0913 %	641,136	0.0913 %	266 M CHF

Name	Equities	%	Valuation
Aristotle Capital Management LLC 0.0388 %	2,178,682	0.0388 %	112 M CHF
Saratoga Research & Investment Management 0.0326 %	1,832,770	0.0326 %	95 M CHF
Boston Common Asset Management LLC 0.006038 %	339,393	0.006038 %	18 M CHF
Old National Bank (Investment Management) 0.004557 %	256,122	0.004557 %	13 M CHF
Altrius Capital Management, Inc. 0.003486 %	195,954	0.003486 %	10 M CHF

Name	Equities	%	Valuation
Hoffmann Family 64.97 %	69,318,000	64.97 %	29 377 M CHF
Maja Oeri 3.792 %	4,045,950	3.792 %	1 715 M CHF
Melchior Oeri 3.792 %	4,045,950	3.792 %	1 715 M CHF
Severin Schwan 0.2493 %	265,962	0.2493 %	113 M CHF
Towers Watson Investment Management Ltd. 0.141 %	150,384	0.141 %	64 M CHF

List of ROCHE HOLDING AG shareholders

Holdings: Roche Holding AG

Name	Equities	%	Valuation
CHUGAI PHARMACEUTICAL CO., LTD. 59.89%	1,005,670,000	59.89%	53 025 M $
ENTRADA THERAPEUTICS, INC. 6.72%	2,569,115	6.72%	26 M $
ALIGOS THERAPEUTICS, INC. 8.24%	441,038	8.24%	4 M $

Company details: Roche Holding AG

Roche Holding AG

Grenzacherstrasse 124

4058, Basel

+41 61 688 88 80

http://www.roche.com

Group companies: Roche Holding AG

Name	Category and Sector
Sapac Corp. Ltd.
Roche Pharmholding BV Roche Pharmholding BV Medical DistributorsDistribution Services Manufactures and distributes pharmaceutical and vitamin products	Medical Distributors
Roche Pharmholding BV Roche Pharmholding BV Medical DistributorsDistribution Services Manufactures and distributes pharmaceutical and vitamin products	Medical Distributors
Roche Intertrade Ltd.
Roche Intertrade Ltd.

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ROCHE HOLDING AG	-0.64%	+1.63%	+23.88%	+25.54%	367B
ELI LILLY AND COMPANY	+3.66%	+2.03%	+21.58%	+213.39%	947B
JOHNSON & JOHNSON	+0.93%	+5.61%	+56.34%	+46.91%	578B
ABBVIE INC.	+2.01%	+0.19%	+15.78%	+54.07%	395B
MERCK & CO., INC.	+1.82%	+10.57%	+38.48%	+17.21%	303B
ASTRAZENECA PLC	+0.89%	+3.71%	+19.67%	+33.31%	298B
NOVARTIS AG	+0.57%	+4.66%	+22.77%	+51.56%	295B
AMGEN INC.	+4.49%	+12.41%	+29.06%	+57.61%	207B
NOVO NORDISK A/S	+5.29%	-20.04%	-53.46%	-38.31%	208B
GILEAD SCIENCES, INC.	+2.10%	+7.43%	+55.55%	+76.59%	189B
Average	+1.77%	+2.72%	+22.96%	+53.79%	378.65B
Weighted average by Cap.	+1.62%	+2.84%	+25.79%	+81.55%